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Ginger for chemotherapy-induced nausea and vomiting?
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Protocol for a double-blind placebo-controlled randomized trial 
Ginger may have the potential to act as an adjuvant therapy for chemotherapy-induced nausea and vomiting (CINV). Despite advances in anti-cancer
treatments and anti-emetic medication, low risk and cost-effective therapies to improve nausea-related QoL, symptom management and ultimately the
survival of patients undergoing chemotherapy are needed.
Research aim: To assess the efficacy (reduced incidence and severity of CINV, enhanced quality of life), safety, cost-effectiveness, and impact on gut 
microbiota of a standardized adjuvant ginger root supplement. 
• Study Design: Multi-centre double-blind placebo-controlled randomized trial.
• Recruitment: Two hospitals in Brisbane, Queensland, Australia up until April 2019. Target sample size: N=300.
• Supplementation Schedule: 4x 300mg over-encapsulated capsules of ginger per day (1.2g ginger/60mg gingerols per day) OR 4x 300mg over-
encapsulated capsules of placebo per day (1.2g inner filler microcrystalline cellulose) → 1x capsule every 3-4 hours → capsules consumed for 5 days →
commencing Day 1 of CTx Cycle 1→ For Cycles 1 to 3.
• Alterations to Standard Care: No changes to standard care. Use of anti-emetic medications prescribed by medical teams permitted during the trial.
Outcomes
This study, aimed to be completed in April 2019, will:
✓ evaluate the safety of ginger supplementation;
✓ examine the ginger formulation and dosing regimen needed;
✓ control potential confounders;
✓ indicate the capacity of ginger to ameliorate CINV-related effects such as fatigue and compromised nutrition.
INCLUDED
• Chemotherapy-naïve
• Moderately to highly emetogenic CTX
• Single-day CTX regimen
• Age >18 years
• English speaking
• Adequate physical function 
• Ability to safely swallow capsules
• Cognitive ability to understand study purpose and adhere to study
EXCLUDED
• Concurrent radiotherapy
• Concurrent use of ginger in food/supplement/drinks
• History of adverse event to ginger
• Prescribed anti-coagulants, NSAIDs or hypoglycaemics
• Self-prescribed nausea therapies
• Chronic alcohol use (>14 standard drinks per week)
• Experiencing nausea and/or vomiting for reasons other than CTx
• Gall stones or liver disease
• Thrombocytopenia
• Pregnant or lactating women
Eligibility Criteria
Intervention
Introduction
Timepoint T0 T1 T2 T3 T4
Pre- CTX Day 
before 
CTX
Day of 
CTX
4-days 
post-CTX
5-8 days 
post-CTX
CTX cycle (C) 1 only 1 - 3 1 - 3 1 - 3 1 - 3
Screened and consented ✓
Participant characteristics ✓
Delivery of supplements ✓
Delivery of Participant Booklet ✓
Nutrition status (Scored PG-
SGA)
✓ ✓ (C2-3)
Supplements consumed ✓ ✓
CIN-related QoL (FLIE-5DR) ✓ ✓
Global QoL (EQ-5D-5L) ✓ ✓
Anticipatory nausea and 
vomiting
✓
Nausea and vomiting (MAT) ✓ ✓
Depression and anxiety (HADS) ✓
Fatigue (FACIT-F) ✓ ✓
Health service use ✓ (C3)
Blinding and adherence ✓
Concurrent ginger intake ✓ ✓ ✓ ✓ ✓
Adverse events ✓
Stool swab sample ✓ ✓
Study Procedure
Results
• N=38 recruited from Site A since commencing October 2017. 
Recruitment expected to commence at Site B July 2018. 
• 85% response rate.
• 55% female; mean age 59 ± 12 years; 36% lung cancer, 21% breast, 
12% lymphoma, 24% other.
• No reported serious adverse events relatable to the study intervention.
